sb 203580 has been researched along with formazans in 2 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (formazans) | Trials (formazans) | Recent Studies (post-2010) (formazans) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 1,206 | 2 | 230 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Duschl, A; Eder, K; Fischäder, G; Lehmann, I; Oostingh, GJ; Röder-Stolinski, C | 1 |
Han, X; Han, YC; Li, BL; Li, ZQ; Mi, XY; Song, M; Sun, LM; Wang, EH; Wang, R; Zhao, Y | 1 |
2 other study(ies) available for sb 203580 and formazans
Article | Year |
---|---|
Chlorobenzene induces the NF-kappa B and p38 MAP kinase pathways in lung epithelial cells.
Topics: Cell Line; Chemokine CCL2; Chlorobenzenes; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Formazans; Gene Expression; Humans; Imidazoles; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pulmonary Alveoli; Pyridines; Respiratory Mucosa; RNA, Messenger; Tetrazolium Salts; Tumor Necrosis Factor-alpha | 2008 |
Integrin β3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Line, Tumor; Cell Survival; Chi-Square Distribution; Enzyme Inhibitors; Female; Formazans; Humans; Imidazoles; Immunohistochemistry; Integrin beta3; Middle Aged; p38 Mitogen-Activated Protein Kinases; Pyridines; Retrospective Studies; Tenascin; Tetrazolium Salts; Urokinase-Type Plasminogen Activator | 2010 |